FDA Briefing Document Oncologic Drugs Advisory Committee Meeting May 2, 2013 NDA[removed] – 001 Melblez Kit Delcath Systems, Inc. - Delcath Systems - Document - PDFSEARCH.IO

First Page		Document Content
Delcath Systems Inc. Hepatocellular carcinoma Uveal melanoma Ipilimumab Immunotherapy End point of clinical trials DecisionDx-UM Sunitinib Medicine Hepatology Melanoma		FDA Briefing Document Oncologic Drugs Advisory Committee Meeting May 2, 2013 NDA[removed] – 001 Melblez Kit Delcath Systems, Inc. Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 221,57 KB Share Document on Facebook

	Final Results of a Phase II Multicenter Trial of HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab Combination Treatment in Patients with Stage IIIB-IV Unresectable or Metastatic Melanoma Abstract #1664 DocID: 1v2ur - View Document
	Tumor response from Phase II study of combination treatment of intratumoral HF10, a replication - competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melano DocID: 1uTz9 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. YERVOY® (ipilimumab) injection, for int DocID: 1tcyu - View Document
	Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile. Photo courtesy of Dina Potter. Sunny Tree. 48" × 60". DocID: 1rePY - View Document
	Frågeformulär för sjuksköterska Patientdata Triageguide för Immunrelaterade biverkningar av Ipilimumab: Kryssa i de frågor som du frågat om. DocID: 1ejTe - View Document